Citius Pharmaceuticals Inc vs Super Micro Computer Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Super Micro Computer Inc trades at $37.29 (market cap $20.44B). The key difference: Super Micro Computer Inc is far larger — about 1021.5× Citius Pharmaceuticals Inc's market cap, and Super Micro Computer Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | SMCI | |
|---|---|---|
Market Cap | $20.01M | $20.44B |
Sector | Health | Technology |
52-Week High | $1.82 | $58.68 |
52-Week Low | $0.48 | $20.53 |
Enterprise Value | $16.23M | $27.96B |
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.
Super Micro Computer (SMCI) stock trades at $37.55, up 19.4% on strong Q4 2026 earnings that beat estimates with EPS of $1.70 versus $0.923 expected. The company reported 93% revenue growth year-over-year and issued aggressive fiscal 2027 revenue guidance of $65–72 billion. Technical indicators show a bullish trend with moving averages supporting upside, while RSI levels suggest potential overbought conditions near-term.
The outlook remains positive driven by robust AI infrastructure demand, but risks include execution challenges in meeting high growth targets and competitive pressures. Analyst consensus is a Buy with a $40.40 price target, indicating 7.6% upside from current levels, though margin compression and supply chain delays pose headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →